MaxCyte, Inc. (MXCT)Healthcare | Medical Devices | Rockville, United States | NasdaqGS
0.87 USD
+0.01
(1.210%)
⇧
(April 21, 2026, 10:50 a.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:42 a.m. EDT
Despite a technical bounce in the underlying price over the last two weeks, the winners are sampling the wrong breeze - the short-term forecast models overwhelmingly predict a 23% drop, and the options market is expiring massive put interest near current prices. The news of systemic earnings misses and, more critically, the impending Nasdaq delisting risk due to bid price deficiency creates a toxic overhang that neutralizes any recovery thesis. Immediate execution to sell calls or buy puts is dictated by the delisting timer and the forecasting wreckage; for long-term holders, positioning has shifted to a 'distress sale' rally play rather than a genuine turnaround. The 0.16 revenue growth and negative cash flow confirm the company is burning capital, making the current price a value trap rather than a bargain. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.191898 |
| AutoARIMA | 0.318414 |
| AutoETS | 0.318419 |
| MSTL | 0.320147 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.561 |
| Excess Kurtosis | 0.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.463 |
| Revenue per Share | 0.31 |
| Market Cap | 92,969,440 |
| Forward P/E | -3.26 |
| Beta | 1.45 |
| Profit Margins | -135.14% |
| Website | https://www.maxcyte.com |
As of April 19, 2026, 12:42 a.m. EDT: Options flow indicates heavy speculative positioning at the $2.50 strike for October 2026, with significant Open Interest (102 contracts) despite low volume, suggesting a belief in price recovery to that level. However, the IMMEDIATE short-term (4/17) shows extreme fear in the_puts market, with 33.13% implied volatility compared to 13.75% in calls. This disparity, combined with open interest concentrated in deep OTM puts, signals that the market is pricing in a near-term decline to test lower support levels before attempting any recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6849817 |
| Address1 | 9,713 Key West Avenue |
| Address2 | Suite 400 |
| All Time High | 17.44 |
| All Time Low | 0.643 |
| Ask | 1.1 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 748,160 |
| Average Daily Volume3 Month | 1,183,803 |
| Average Volume | 1,183,803 |
| Average Volume10Days | 748,160 |
| Beta | 1.452 |
| Bid | 0.6018 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.606 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.87 |
| Current Ratio | 8.297 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.87 |
| Day Low | 0.8449 |
| Debt To Equity | 10.463 |
| Display Name | MaxCyte |
| Earnings Call Timestamp End | 1,774,384,200 |
| Earnings Call Timestamp Start | 1,774,384,200 |
| Earnings Timestamp | 1,774,382,400 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -40,222,000 |
| Ebitda Margins | -1.21789 |
| Enterprise To Ebitda | -0.168 |
| Enterprise To Revenue | 0.205 |
| Enterprise Value | 6,757,083 |
| Eps Current Year | -0.30039 |
| Eps Forward | -0.26708 |
| Eps Trailing Twelve Months | -0.42 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.7684 |
| Fifty Day Average Change | 0.10159999 |
| Fifty Day Average Change Percent | 0.13222279 |
| Fifty Two Week Change Percent | -68.49817 |
| Fifty Two Week High | 2.955 |
| Fifty Two Week High Change | -2.085 |
| Fifty Two Week High Change Percent | -0.7055838 |
| Fifty Two Week Low | 0.643 |
| Fifty Two Week Low Change | 0.227 |
| Fifty Two Week Low Change Percent | 0.35303265 |
| Fifty Two Week Range | 0.643 - 2.955 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 105,709,462 |
| Forward Eps | -0.26708 |
| Forward P E | -3.2574508 |
| Free Cashflow | -15,469,750 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.8116 |
| Gross Profits | 26,804,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01398 |
| Held Percent Institutions | 0.65808 |
| Implied Shares Outstanding | 106,861,428 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. |
| Long Name | MaxCyte, Inc. |
| Market | us_market |
| Market Cap | 92,969,440 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_4048262 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -44,630,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 91,516,126 |
| Number Of Analyst Opinions | 4 |
| Open | 0.8596 |
| Operating Cashflow | -34,410,000 |
| Operating Margins | -0.94808 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 301 944 1700 |
| Previous Close | 0.8596 |
| Price Eps Current Year | -2.8962348 |
| Price Hint | 4 |
| Price To Book | 0.5417186 |
| Price To Sales Trailing12 Months | 2.815038 |
| Profit Margins | -1.35136 |
| Quick Ratio | 7.468 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | 0.010399997 |
| Regular Market Change Percent | 1.2098647 |
| Regular Market Day High | 0.87 |
| Regular Market Day Low | 0.8449 |
| Regular Market Day Range | 0.8449 - 0.87 |
| Regular Market Open | 0.8596 |
| Regular Market Previous Close | 0.8596 |
| Regular Market Price | 0.87 |
| Regular Market Time | 1,776,783,059 |
| Regular Market Volume | 295,723 |
| Return On Assets | -0.12595001 |
| Return On Equity | -0.23629999 |
| Revenue Growth | -0.16 |
| Revenue Per Share | 0.31 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 106,861,428 |
| Shares Percent Shares Out | 0.051999997 |
| Shares Short | 5,552,543 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,754,015 |
| Short Name | MaxCyte, Inc. |
| Short Percent Of Float | 0.0523 |
| Short Ratio | 5.36 |
| Source Interval | 15 |
| State | MD |
| Symbol | MXCT |
| Target High Price | 5.0 |
| Target Low Price | 2.43 |
| Target Mean Price | 4.1075 |
| Target Median Price | 4.5 |
| Total Cash | 103,044,000 |
| Total Cash Per Share | 0.964 |
| Total Debt | 17,943,000 |
| Total Revenue | 33,026,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.38143 |
| Two Hundred Day Average Change | -0.51143 |
| Two Hundred Day Average Change Percent | -0.37021783 |
| Type Disp | Equity |
| Volume | 295,723 |
| Website | https://www.maxcyte.com |
| Zip | 20,850 |